A Dream of First-World Drug Quality for Third-World India is Deferred
This article was originally published in The Gold Sheet
Executive Summary
He prevented his employer from selling substandard drugs in the US. But could Ranbaxy whistleblower Dinesh Thakur convince India to demand higher quality drugs for its own citizens?
You may also be interested in...
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.
US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.